Efficacy Profiles of Daptomycin for Treatment of Invasive and Noninvasive Pulmonary Infections with Streptococcus pneumoniae
| Autor: | James C. Paton, Dirk Wedekind, Thomas Welsh, A. David Ogunniyi, Stefanie Henken, Ulrich A. Maus, David E. Briles, Jennifer Bohling, Stefanie M. Bode-Böger, Vyvyan Salisbury, Franz Bange, Tobias Welte, Jens Martens-Lobenhoffer |
|---|---|
| Přispěvatelé: | Henken, Stefanie, Bohling, Jennifer, Martens-Lobenhoffer, Jens, Paton, James C, Ogunniyi, A David, Briles, David E, Salisbury, Vyvyan C, Wedekind, Dirk, Bode-Boeger, Stefanie, Welsh, Thomas, Bange, Franz C, Welte, Tobias, Maus, Ulrich A |
| Rok vydání: | 2010 |
| Předmět: |
daptomycin
experimental meningitis bacterial loads medicine.disease_cause Microbiology antbiotics Pneumococcal Infections Mice Daptomycin Sepsis Streptococcus pneumoniae Animals Medicine Experimental Therapeutics Pharmacology (medical) Pharmacology & Pharmacy septic pneumococcal disease Antibacterial agent Pharmacology business.industry Ceftriaxone Bacterial pneumonia Pneumonia Pneumococcal pneumococcal disease bacterial infections and mycoses medicine.disease respiratory tract diseases Anti-Bacterial Agents Mice Inbred C57BL Disease Models Animal Pneumonia Pneumococcal infections Infectious Diseases lipopeptide Immunology Pneumococcal pneumonia business medicine.drug |
| Zdroj: | Antimicrobial Agents and Chemotherapy. 54:707-717 |
| ISSN: | 1098-6596 0066-4804 |
| Popis: | Daptomycin is a novel lipopeptide antibiotic with excellent activity against Gram-positive bacterial pathogens, but its therapeutic value for the treatment of invasive pneumococcal disease compared to that for the treatment of pneumococcal pneumonia is incompletely defined. We investigated the efficacy of daptomycin in two models of Streptococcus pneumoniae -induced lung infection, i.e., pneumococcal pneumonia and septic pneumococcal disease. Mice were infected with a bioluminescent, invasive serotype 2 S. pneumoniae strain or a less virulent serotype 19 S. pneumoniae strain and were then given semitherapeutic or therapeutic daptomycin or ceftriaxone. Readouts included survival; bacterial loads; and septic disease progression, as determined by biophotonic imaging. Semitherapeutic daptomycin treatment fully protected the mice against the progression of septic disease induced by serotype 2 S. pneumoniae , while therapeutic treatment of the mice with daptomycin or ceftriaxone led to ∼70% or ∼60% survival, respectively. In contrast, mice infected with serotype 19 S. pneumoniae developed severe pneumonia and lung leakage even in the presence of increased intra-alveolar daptomycin levels, resulting in only 40% survival, whereas the ceftriaxone-treated mice had 100% survival. Together, although daptomycin demonstrates little efficacy in the treatment of pneumococcal pneumonia, daptomycin is highly effective in preventing S. pneumoniae -induced septic death, thus possibly offering a therapeutic option for patients with life-threatening septic pneumococcal disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|